Apoglyx: New substance provides gentle diabetes medication

New therapy against type 2 diabetes

Apoglyx: New substance provides gentle diabetes medication

In type 2 diabetes, the body’s glucose control mechanism does not work very well, and many patients instead need to take insulin or other medication to stabilise their blood sugar levels. Normally, the blood sugar level is regulated by reducing the secretion of glucose from the liver, but in people with type 2 diabetes this mechanism is also disturbed and glucose is produced even when it is not needed.

Stop unnecessary sugar

Apoglyx attacks this unnecessary glucose production with its substance, which patients can easily take as a pill. Too high glucose levels in the blood result in future complications such as impaired renal function, nerve damage and cardiovascular disease.

“By reducing the flow of glucose from the liver this way in diabetics, they can reduce their intake of insulin. This decreases the risk of too low glucose levels, which is common when taking insulin and which sometimes leads to unconsciousness. As far as we know, no one but us has patented a substance with this type of mechanism”, says Martina Reimer Kvist, CEO of Apoglyx.

About to license the project

The fact that Apoglyx’s substance actually inhibits glucose secretion from the liver has been shown by the researchers through lab experiments using mice. More animal studies are currently underway.

“The goal is to license the substance when it reaches the clinical phase, which we expect to take place in 2018”, she says.

The company raised SEK 5 million in venture capital in 2016, and expects it will need to raise more funds in 2017. The number of diabetics in the world is increasing, and in 2016 there were approximately 400 million.

Updated: 12 June 2017

Text: Elisabet Ottosson